A look at autoimmunity and inflammation in the eye

Journal of Clinical Investigation

Volumn 120, Issue 9, 2010, Pages 3073-3083

  Caspi, Rachel R ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN; DACLIZUMAB; INTERLEUKIN 17; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHORIORETINOPATHY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG TARGETING; EYE INFLAMMATION; HUMAN; IMMUNE RESPONSE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SYMPATHETIC OPHTHALMIA; UVEITIS;

ANIMALS; AUTOIMMUNITY; DISEASE MODELS, ANIMAL; EYE; FORECASTING; HUMANS; INFLAMMATION; MACACA FASCICULARIS; MACACA MULATTA; MICE; MICE, NUDE; MICE, TRANSGENIC; RATS; RATS, INBRED LEW; RETINA; UVEITIS;

EID: 77956389310     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42440     Document Type: Review

References (122)

1. Gery I, Nussenblatt RB, Chan CC, Caspi RR. Autoimmune diseases of the eye. In: Theofilopoulos AN, Bona CA, eds. The Molecular Pathology of Autoimmune Diseases. New York, New York, USA: Taylor and Francis; 2002:978-998.
2. Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491-500.
3. Nussenblatt RB, Whitcup SM. Uveitis: Fundamentals and Clinical Practice. Philadelphia, Pennsylvania, USA: Mosby Publishing; 2004.
4. Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2001;42(9):2004-2009.
5. Gery I, Mochizuki M, Nussenblatt RB. Retinal specific antigens and immunopathogenic processes they provoke. Prog Retinal Res. 1986;5:75-109.
6. Pennesi G, Caspi RR. Genetic control of susceptibility in clinical and experimental uveitis. Int Rev Immunol. 2002;21(2-3):67-88.
7. Caspi RR. Mouse models of autoimmune and immune-mediated uveitis. In: Chalupa L, ed. Eye, Retina, and Visual System of the Mouse. Cambridge, Massachusetts, USA: MIT Press; 2008: 513-526.
8. Caspi RR. Animal models of autoimmune and immune-mediated uveitis. Drug Discov Today: Disease Models. 2006;3(1):3-10.
9. Streilein JW. Ocular immune privilege: the eye takes a dim but practical view of immunity and inflammation. J Leukoc Biol. 2003;74(2):179-185.
10. Medawar P. Immunity to homologous grafted skin III. The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol. 1948;29(1):58-69.
11. Avichezer D, et al. An immunologically privileged retinal antigen elicits tolerance: major role for central selection mechanisms. J Exp Med. 2003;198(11):1665-1676.
12. Gotter J, Brors B, Hergenhahn M, Kyewski B. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med. 2004;199(2):155-166.
13. Anderson MS, et al. Projection of an immunological self shadow within the thymus by the aire protein. Science. 2002;298(5597):1395-1401.
14. Mathis D, Benoist C. Aire. Annu Rev Immunol. 2009;27:287-312.
15. Egwuagu CE, Charukamnoetkanok P, Gery I. Thymic expression of autoantigens correlates with resistance to autoimmune disease. J Immunol. 1997;159(7):3109-3112.
16. Takase H, et al. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. Int Immunol. 2005;17(8):1131-1140.
17. de Smet MD, Dayan M, Nussenblatt RB. A novel method for the determination of T-cell proliferative responses in patients with uveitis. Ocul Immunol Inflamm. 1998;6(3):173-178.
18. Tan LC, et al. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162(3):1827-1835.
19. Wildner G, Diedrichs-Mohring M. Autoimmune uveitis and antigenic mimicry of environmental antigens. Autoimmun Rev. 2004;3(5):383-387.
20. McPherson SW, Roberts JP, Gregerson DS. Systemic expression of rat soluble retinal antigen induces resistance to experimental autoimmune uveoretinitis. J Immunol. 1999;163(8):4269-4276.
21. Xu H, et al. Transgenic expression of an immunologically privileged retinal antigen extraocularly enhances self tolerance and abrogates susceptibility to autoimmune uveitis. Eur J Immunol. 2000;30(1):272-278.
22. Agarwal RK, Kang Y, Zambidis E, Scott DW, Chan CC, Caspi RR. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J Clin Invest. 2000;106(2):245-252.
23. Silver PB, et al. Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells. J Immunol. 2007;179(8):5146-5158.
24. Caspi RR. Ocular autoimmunity: the price of privilege? Immunol Rev. 2006;213:23-35.
25. Rosenbaum JT, McDevitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980;286(5773):611-613.
26. Li Q, Peng B, Whitcup SM, Jang SU, Chan CC. Endotoxin induced uveitis in the mouse: susceptibility and genetic control. Exp Eye Res. 1995;61(5):629-632.
27. Nussenblatt RB. Bench to bedside: new approaches to the immunotherapy of uveitic disease. Int Rev Immunol. 2002;21(2-3):273-289.
28. Gregerson DS. Peripheral expression of ocular antigens in regulation and therapy of ocular autoimmunity. Int Rev Immunol. 2002;21(2-3):101-121.
29. Taneja V, David CS. HLA class II transgenic mice as models of human diseases. Immunol Rev. 1999;169:67-79.
30. Pennesi G, et al. A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest. 2003;111(8):1171-1180.
31. de Smet MD, Bitar G, Roberge FG, Gery I, Nussenblatt RB. Human S-antigen: presence of multiple immunogenic and immunopathogenic sites in the Lewis rat. J Autoimmun. 1993;6(5):587-599.
32. DeVoss J, et al. Spontaneous autoimmunity prevented by thymic expression of a single self-antigen. J Exp Med. 2006;203(12):2727-2735.
33. Szpak Y, et al. Spontaneous retinopathy in HLA-A29 transgenic mice. Proc Natl Acad Sci U S A. 2001;98(5):2572-2576.
34. de Kozak Y, Camelo S, Pla M. Pathological aspects of spontaneous uveitis and retinopathy in HLA-A29 transgenic mice and in animal models of retinal autoimmunity: relevance to human pathologies. Ophthalmic Res. 2008;40(3-4):175-180.
35. Rosenzweig HL, et al. NOD2, the gene responsible for familial granulomatous uveitis, in a mouse model of uveitis. Invest Ophthalmol Vis Sci. 2008;49(4):1518-1524.
36. Lin X, Li S, Xie C, Huang X, Fan Z. Experimental studies of melanin associated antigen and its relationship with sympathetic ophthalmia and Vogt-Kayanagi-Harada syndrome. Yan Ke Xue Bao. 2003;19(3):184-186, 200.
37. Nussenblatt RB, Mittal KK, Ryan S, Green WR, Maumenee AE. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am J Ophthalmol. 1982;94(2):147-158.
38. Caspi RR, Grubbs BG, Chan CC, Chader GJ, Wiggert B. Genetic control of susceptibility to experimental autoimmune uveoretinitis in the mouse model. Concomitant regulation by MHC and non-MHC genes. J Immunol. 1992;148(8):2384- 2389.
39. Mattapallil MJ, et al. Differentially expressed genes in MHC-compatible rat strains that are susceptible or resistant to experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2008;49(5):1957-1970.
40. Kulkarni P. Review: uveitis and immunosuppressive drugs. J Ocul Pharmacol Ther. 2001;17(2):181-187.
41. Nussenblatt RB, et al. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A. 1999;96(13):7462-7466.
42. Zhang M, et al. T cell tolerance to a neo-self antigen expressed by thymic epithelial cells: the soluble form is more effective than the membrane-bound form. J Immunol. 2003;170(8):3954-3962.
43. Ham DI, et al. Central immunotolerance in transgenic mice expressing a foreign antigen under control of the rhodopsin promoter. Invest Ophthalmol Vis Sci. 2004;45(3):857-862.
44. Lambe T, et al. Limited peripheral T cell anergy predisposes to retinal autoimmunity. J Immunol. 2007;178(7):4276-4283.
45. Sakaguchi S, Sakaguchi N. Regulatory T cells in immunologic self-tolerance and autoimmune disease. Int Rev Immunol. 2005;24(3-4):211-226.
46. Grajewski RS, et al. Endogenous IRBP can be dispensable for generation of natural CD4+CD25+ regulatory T cells that protect from IRBP-induced retinal autoimmunity. J Exp Med. 2006;203(4):851-856.
47. Gregerson DS, Heuss ND, Lehmann U, McPherson SW. Peripheral induction of tolerance by retinal antigen expression. J Immunol. 2009;183(2):814-822.
48. Wildner G, Diedrichs-Moehring M. Multiple autoantigen mimotopes of infectious agents induce autoimmune arthritis and uveitis in lewis rats. Clin Diagn Lab Immunol. 2005;12(5):677-679.
49. Singh VK, Usukura J, Shinohara T. Molecular mimicry: uveitis induced in Macaca fascicularis by microbial protein having sequence homology with retinal S-antigen. Jpn J Ophthalmol. 1992;36(1):108-116.
50. Shinohara T, Singh VK, Tsuda M, Yamaki K, Abe T, Suzuki S. S-antigen: from gene to autoimmune uveitis. Exp Eye Res. 1990;50(6):751-757.
51. Prendergast RA, et al. T cell traffic and the inflammatory response in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 1998;39(5):754-762.
52. Thurau SR, et al. The fate of autoreactive, GFP+ T cells in rat models of uveitis analyzed by intravital fluorescence microscopy and FACS. Int Immunol. 2004;16(11):1573-1582.
53. Jiang HR, Lumsden L, Forrester JV. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest Ophthalmol Vis Sci. 1999;40(13):3177-3185.
54. Gregerson DS, Sam TN, McPherson SW. The antigen-presenting activity of fresh, adult parenchymal microglia and perivascular cells from retina. J Immunol. 2004;172(11):6587-6597.
55. Chen J, et al. A unique pattern of up- and down-regulation of chemokine receptor CXCR3 on inflammation-inducing Th1 cells. Eur J Immunol. 2004;34(10):2885-2894.
56. Caspi RR, et al. Recruitment of antigen-nonspecific cells plays a pivotal role in the pathogenesis of a T cell-mediated organ-specific autoimmune disease, experimental autoimmune uveoretinitis. J Neuroimmunol. 1993;47(2):177-188.
57. Su SB, et al. Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency. Invest Ophthalmol Vis Sci. 2007;48(10):4616-4625.
58. Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis. J Immunol. 1998;161(1):122-127.
59. Grajewski RS, et al. Activation of invariant NKT cells ameliorates experimental ocular autoimmunity by a mechanism involving innate IFN-gamma production and dampening of the adaptive Th1 and Th17 responses. J Immunol. 2008;181(7):4791-4797.
60. Nicholson LB, Raveney BJ, Munder M. Monocyte dependent regulation of autoimmune inflammation. Curr Mol Med. 2009;9(1):23-29.
61. Cui Y, et al. Major role of gamma delta T cells in the generation of IL-17+ uveitogenic T cells. J Immunol. 2009;183(1):560-567.
62. Horwitz DA, Zheng SG, Gray JD. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008;29(9):429-435.
63. Stein-Streilein J, Taylor AW. An eye's view of T regulatory cells. J Leukoc Biol. 2007;81(3):593-598.
64. Stein-Streilein J, Streilein JW. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int Rev Immunol. 2002;21(2-3):123-152.
65. Kitaichi N, Namba K, Taylor AW. Inducible immune regulation following autoimmune disease in the immune-privileged eye. J Leukoc Biol. 2005;77(4):496-502.
66. Taylor A. A review of the influence of aqueous humor on immunity. Ocul Immunol Inflamm. 2003;11(4):231-241.
67. Chen L, et al. Decreased frequency and diminished function of CD4+CD25high regulatory T cells are associated with active uveitis in patients with Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci. 2008;49(8):3475-3482.
68. Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatani N. Decreased percentages of regulatory T cells in peripheral blood of patients with Behcet's disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol. 2008;18(4):354-358.
69. Ke Y, Jiang G, Sun D, Kaplan HJ, Shao H. Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest Ophthalmol Vis Sci. 2008;49(9):3999-4007.
70. Agarwal RK, Caspi RR. Rodent models of experimental autoimmune uveitis. Methods Mol Med. 2004;102:395-419.
71. McPherson SW, Yang J, Chan CC, Dou C, Gregerson DS. Resting CD8 T cells recognize beta-galactosidase expressed in the immune-privileged retina and mediate autoimmune disease when activated. Immunology. 2003;110(3):386-396.
72. Song L, Le J, Ye F, Shao H, Kaplan HJ, Sun D. Sequence 168 to 177 of interphotoreceptor retinoid-binding protein (IRBP) is an antigenic epitope for autoreactive CD8 T cells in the B10RIII mouse. J Neuroimmunol. 2008;193(1-2):68-76.
73. Shao H, Sun SL, Kaplan HJ, Sun D. Characterization of rat CD8+ uveitogenic T cells specific for interphotoreceptor retinal-binding protein 1177-1191. J Immunol. 2004;173(4):2849-2854.
74. Calder VL, Zhao ZS, Wang Y, Barton K, Lightman SL. Effects of CD8 depletion on retinal soluble antigen induced experimental autoimmune uveoretinitis. Immunology. 1993;79(2):255-262.
75. Caspi RR, Kuwabara T, Nussenblatt RB. Characterization of a suppressor cell line which downgrades experimental autoimmune uveoretinitis in the rat. J Immunol. 1988;140(8):2579-2584.
76. Han G, et al. Suppressor role of rat CD8+CD45RClow T cells in experimental autoimmune uveitis (EAU). J Neuroimmunol. 2007;183(1-2):81-88.
77. Peng Y, et al. Minimally activated CD8 autoreactive T cells specific for IRBP express a high level of Foxp3 and are functionally suppressive. Invest Ophthalmol Vis Sci. 2007;48(5):2178-2184.
78. Luger D, Caspi RR. New perspectives on effector mechanisms in uveitis. Semin Immunopathol. 2008;30(2):135-143.
79. Amadi-Obi A, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007;13(6):711-718.
80. Luger D, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med. 2008;205(4):799-810.
81. Caspi RR, et al. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J Immunol. 1994;152(2):890-899.
82. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: Adversaries and collaborators. Ann N Y Acad Sci. 2010;1183:211-221.
83. Tang J, Zhu W, Silver PB, Su SB, Chan CC, Caspi RR. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol. 2007;178(9):5578-5587.
84. Zhao C, et al. S-antigen specific T helper type 1 response is present in Behcet's disease. Mol Vis. 2008;14:1456-1464.
85. Chi W, et al. IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol. 2007;119(5):1218-1224.
86. Chi W, et al. Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Invest Ophthalmol Vis Sci. 2008;49(7):3058-3064.
87. Ooi KG, Galatowicz G, Calder VL, Lightman SL. Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype? Clin Med Res. 2006;4(4):294-309.
88. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002;2(2):85-95.
89. Nussenblatt RB, Dinning WJ, Fujikawa LS, Chan CC, Palestine AG. Local cyclosporine therapy for experimental autoimmune uveitis in rats. Arch Ophthalmol. 1985;103(10):1559-1562.
90. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617-637.
91. Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm. 2009;17(6):403-414.
92. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18(6):481-486.
93. Liang W, et al. B-cell delivered gene transfer of human S-Ag-Ig fusion protein protects from experimental autoimmune uveitis. Clin Immunol. 2006;118(1):35-41.
94. Martin AP, et al. Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2005;46(6):2056-2063.
95. Honey K. The comeback kid: TYSABRI now FDA approved for Crohn disease. J Clin Invest. 2008;118(3):825-826.
96. Whitcup SM, DeBarge LR, Caspi RR, Harning R, Nussenblatt RB, Chan CC. Monoclonal antibodies against ICAM-1 (CD54) and LFA-1 (CD11a/CD18) inhibit experimental autoimmune uveitis. Clin Immunol Immunopathol. 1993;67(2):143-150.
97. Xu H, Manivannan A, Liversidge J, Sharp PF, Forrester JV, Crane IJ. Involvement of CD44 in leukocyte trafficking at the blood-retinal barrier. J Leukoc Biol. 2002;72(6):1133-1141.
98. Crane IJ, et al. Involvement of CCR5 in the passage of Th1-type cells across the blood-retina barrier in experimental autoimmune uveitis. J Leukoc Biol. 2006;79(3):435-443.
99. Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol. 2008;8(12):970-976.
100. Martin TM, Doyle TM, Smith JR, Dinulescu D, Rust K, Rosenbaum JT. Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol. 2003;136(5):933-935.
101. Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F. NOD2-associated diseases: Bridging innate immunity and autoinflammation. Clin Immunol. 2010;134(3):251-261.
102. Wildner G, Diedrichs-Mohring M, Thurau SR. Induction of arthritis and uveitis in Lewis rats by antigenic mimicry of peptides from HLA-B27 and cytokeratin. Eur J Immunol. 2002;32(1):299-306.
103. Ebringer A, Rashid T. B27 disease is a new autoimmune disease that affects millions of people. Ann N Y Acad Sci. 2007;1110:112-120.
104. Nussenblatt RB, Kuwabara T, de Monasterio FM, Wacker WB. S-antigen uveitis in primates. A new model for human disease. Arch Ophthalmol. 1981;99(6):1090-1092.
105. Fujino Y, et al. Immunopathology of experimental autoimmune uveoretinitis in primates. Autoimmunity. 1992;13(4):303-309.
106. Gregerson DS, Torseth JW, McPherson SW, Roberts JP, Shinohara T, Zack DJ. Retinal expression of a neo-self antigen, beta-galactosidase, is not tolerogenic and creates a target for autoimmune uveoretinitis. J Immunol. 1999;163(2):1073-1080.
107. Terrada C, et al. Regulatory T cells control uveoretinitis induced by pathogenic Th1 cells reacting to a specific retinal neoantigen. J Immunol. 2006;176(12):7171-7179.
108. Ichikawa T, et al. Spontaneous development of autoimmune uveoretinitis in nude mice following reconstitution with embryonic rat thymus. Clin Exp Immunol. 1991;86(1):112-117.
109. LeHoang P, et al. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am J Ophthalmol. 1992;113(1):33-35.
110. Baarsma GS, Priem HA, Kijlstra A. Association of birdshot retinochoroidopathy and HLA-A29 antigen. Curr Eye Res. 1990;9(suppl):63-68.
111. Kilmartin DJ, Finch A, Acheson RW. Primary association of HLA-B51 with Behcet's disease in Ireland. Br J Ophthalmol. 1997;81(8):649-653.
112. Mizuki N, Inoko H, Tanaka H, Kera J, Tsuiji K, Ohno S. Human leukocyte antigen serologic and DNA typing of Behcet's disease and its primary association with B51. Invest Ophthalmol Vis Sci. 1992;33(12):3332-3340.
113. Arber N, Klein T, Meiner Z, Pras E, Weinberger A. Close association of HLA-B51 and B52 in Israeli patients with Behcet's syndrome. Ann Rheum Dis. 1991;50(6):351-353.
114. Jaakkola E, et al. Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis. Ann Rheum Dis. 2006;65(6):775-780.
115. Brewerton DA. The genetics of acute anterior uveitis. Trans Ophthalmol Soc U K. 1985;104(pt 3):248-249.
116. Numaga J, Islam MS, Mitsui H, Maeda H. [Anterior uveitis with ankylosing spondylitis and HLA]. Nippon Ganka Gakkai Zasshi. 1996;100(4):292-295.
117. Shindo Y, Ohno S, Yamamoto T, Nakamura S, Inoko H. Complete association of the HLA-DRB1*04 and -DQB1*04 alleles with Vogt-Koyanagi-Harada's disease. Hum Immunol. 1994;39(3):169-176.
118. Kim MH, et al. Association of HLA with Vogt-Koyanagi-Harada syndrome in Koreans. Am J Ophthalmol. 2000;129(2):173-177.
119. Kilmartin DJ, et al. Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients. Br J Ophthalmol. 2001;85(3):281-286.
120. Shindo Y, et al. Immunogenetic study of sympathetic ophthalmia. Tissue Antigens. 1997;49(2):111-115.
121. Oruc S, Duffy BF, Mohanakumar T, Kaplan HJ. The association of HLA class II with pars planitis. Am J Ophthalmol. 2001;131(5):657-659.
122. Cuccia Belvedere M, et al. Genetic heterogeneity in uveitis. Dis Markers. 1986;4(3):243-246.